U.S. Markets close in 2 hrs, 34 mins
| Symbol | Value | Change | Percentage Change |
|---|---|---|---|
| DJIA | 9,748.34 | -207.16 | -2.08% |
| NASDAQ | 1,818.71 | -44.25 | -2.38% |
| S&P 500 | 1,032.65 | -24.24 | -2.29% |
| Day Low | — | |
|---|---|---|
| Day High | — |
|
| Range | — | |
| Volume | — | |
| 30-Day Avg. Vol. | 16,000 |
|
| Difference | — | |
| Market Cap. | 39.36 M | |
| Change | 0 | |
| Shares Out. | 12.57 M | |
| Percent Traded | — | |
| Revenue (LFY) | 0 | |
| Earnings (TTM) | -4.13 M | |
| Next Earnings |
|
|
| EPS (TTM) | -0.45 |
| 52-Wk Low 11/16/07 | 2.06 | |
|---|---|---|
| 52-Wk High 8/26/08 | 4.52 |
|
| Range | 2.46 | |
| Prev. Close 10/6/08 | 2.80 | |
| Today's Open | — | |
| Change | — | |
| Dividend (TTM) | 0.00 | |
| Div. Yield (TTM) | 0.00% |
|
| Beta | — | |
| P/E Ratio (TTM) | — | |
| P/E Ratio (Fwd.) | -3.00 |
Catalyst Pharmaceutical Partners may help certain addicts kick the habit. The development-stage company's lead candidate, CPP-109 (based on the chemical compound vigabatrin), is in clinical studies for ... View Full Description
| Earnings/Share(EPS) | Estimate | Actual | Difference |
|---|---|---|---|
| 2 Quarters Ago | — — | — — |
—
—
|
| Last Quarter | — — | — — |
—
—
|
| Quarterly - 06/30/2008 | Annual - 2007 | |
|---|---|---|
| Total Revenue | 0.00 | 0.00 |
| Gross Profit | -8,233.00 | -15,761.00 |
| Operating Income | -2.46 M | -5.03 M |
| Net Income | -2.38 M | -4.14 M |
